TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $26.94 million. The enterprise value is $33.75 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 44.74 million shares outstanding. The number of shares has increased by 64.58% in one year.
| Current Share Class | 44.74M |
| Shares Outstanding | 44.74M |
| Shares Change (YoY) | +64.58% |
| Shares Change (QoQ) | +13.79% |
| Owned by Insiders (%) | 8.42% |
| Owned by Institutions (%) | 27.42% |
| Float | 19.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.34 |
| Forward PS | 0.30 |
| PB Ratio | 4.25 |
| P/TBV Ratio | 5.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.20, with a Debt / Equity ratio of 9.13.
| Current Ratio | 4.20 |
| Quick Ratio | 3.40 |
| Debt / Equity | 9.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.44 |
Financial Efficiency
Return on equity (ROE) is -223.35% and return on invested capital (ROIC) is -31.47%.
| Return on Equity (ROE) | -223.35% |
| Return on Assets (ROA) | -25.12% |
| Return on Invested Capital (ROIC) | -31.47% |
| Return on Capital Employed (ROCE) | -53.21% |
| Weighted Average Cost of Capital (WACC) | 7.99% |
| Revenue Per Employee | $384,091 |
| Profits Per Employee | -$185,794 |
| Employee Count | 209 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, TELA Bio has paid $230,000 in taxes.
| Income Tax | 230,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.50% in the last 52 weeks. The beta is 0.99, so TELA Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -38.50% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 1.28 |
| Relative Strength Index (RSI) | 42.48 |
| Average Volume (20 Days) | 219,654 |
Short Selling Information
The latest short interest is 690,940, so 1.54% of the outstanding shares have been sold short.
| Short Interest | 690,940 |
| Short Previous Month | 577,693 |
| Short % of Shares Out | 1.54% |
| Short % of Float | 3.55% |
| Short Ratio (days to cover) | 8.39 |
Income Statement
In the last 12 months, TELA Bio had revenue of $80.28 million and -$38.83 million in losses. Loss per share was -$0.83.
| Revenue | 80.28M |
| Gross Profit | 54.72M |
| Operating Income | -33.76M |
| Pretax Income | -38.60M |
| Net Income | -38.83M |
| EBITDA | -32.75M |
| EBIT | -33.76M |
| Loss Per Share | -$0.83 |
Full Income StatementBalance Sheet
The company has $50.85 million in cash and $57.65 million in debt, with a net cash position of -$6.81 million or -$0.15 per share.
| Cash & Cash Equivalents | 50.85M |
| Total Debt | 57.65M |
| Net Cash | -6.81M |
| Net Cash Per Share | -$0.15 |
| Equity (Book Value) | 6.31M |
| Book Value Per Share | 0.14 |
| Working Capital | 57.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.22 million and capital expenditures -$448,000, giving a free cash flow of -$28.67 million.
| Operating Cash Flow | -28.22M |
| Capital Expenditures | -448,000 |
| Depreciation & Amortization | 1.01M |
| Net Borrowing | 17.58M |
| Free Cash Flow | -28.67M |
| FCF Per Share | -$0.64 |
Full Cash Flow StatementMargins
Gross margin is 68.17%, with operating and profit margins of -42.05% and -48.37%.
| Gross Margin | 68.17% |
| Operating Margin | -42.05% |
| Pretax Margin | -48.09% |
| Profit Margin | -48.37% |
| EBITDA Margin | -40.79% |
| EBIT Margin | -42.05% |
| FCF Margin | n/a |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -64.58% |
| Shareholder Yield | -64.58% |
| Earnings Yield | -144.15% |
| FCF Yield | -106.42% |
Analyst Forecast
The average price target for TELA Bio is $2.00, which is 232.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.00 |
| Price Target Difference | 232.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TELA Bio has an Altman Z-Score of -5.83 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.83 |
| Piotroski F-Score | 3 |
